Congenital hyperinsulinism (HI) is the most common cause of persistent hypoglycaemia in infants and children. Exendin-(9-39), an inverse glucagon-like peptide 1 (GLP-1) agonist, is a novel therapeutic agent for HI that has demonstrated glucose-raising effect. We report the first population pharmacokinetic (PopPK) model of the exendin-(9-39) in patients with HI and propose the optimal dosing regimen for future clinical trials in neonates with HI.
Introduction
Persistent hypoglycaemia in infants and children is most commonly caused by congenital hyperinsulinism (HI), a rare genetic condition in which pancreatic β-cells fail to suppress insulin secretion when plasma glucose concentrations are low [1] . If inadequately treated, HI can result in permanent brain damage [2] [3] [4] . Therefore, it is imperative to promptly diagnose and initiate appropriate therapy in these children. The estimated incidence of HI is about 1 in 50 000 live births, though it could be significantly higher in regions with high rates of consanguinity [5] .
HI results from mutations in genes that encode proteins that play an important role in the regulation of insulin secretion [4, 6] . The most common and severe form of HI is caused by inactivating mutations in the ATP-sensitive potassium channel (K ATP channel) genes ABCC8 and KCNJ11, which encode SUR1 and Kir6.2 subunits of the channel, respectively [7, 8] . Children affected by this form of HI (K ATP HI) do not respond to the first-line drug therapy, diazoxide, which activates the intact K ATP channel and reduces insulin secretion [1, 9] . In children with diazoxide-unresponsive HI, somatostatin analogues such as octreotide can be used as second-line drug therapy; however, their use in neonates is limited because of potentially severe side effects, particularly, necrotizing enterocolitis [3, 10, 11] . Pancreatectomy should be considered for children who do not respond to drug therapy. Children with focal lesions can be cured by complete excision of the lesion [12, 13] . On the other hand, near-total pancreatectomy performed in diazoxide-refractory patients with the diffuse form of HI as the last resort is associated with high risks of exocrine pancreatic insufficiency and postsurgical diabetes [3, 14] .
Due to the complexity of disease management and the lack of optimal treatment for diazoxide-unresponsive children with diffuse HI, there is a need to develop an alternative drug therapy that is safe and effective. We have strong preclinical and clinical data supporting a novel therapeutic approach employing exendin- in the treatment of HI [15, 16] . Glucagon-like peptide 1 (GLP-1) is an incretin hormone produced by L-cells of the small intestine and is a potent stimulant of postprandial insulin secretion [17] . Exendin-(9-39), a truncated form of exendin-4 (exenatide), is an inverse agonist of the GLP-1 receptor that has been shown to inhibit insulin release induced by GLP-1 and increase peak postprandial glucose levels in healthy volunteers [17, 18] . Data on the pharmacokinetics (PK) of exendin-(9-39) in human subjects are limited. In a study conducted in six healthy volunteers, Edwards et al. [17] reported that the elimination of exendin-(9-39) was characterized by first-order kinetics with a half-life around 33 min, mean clearance of 2.3 ml kg À1 min À1 , and apparent volume of distribution of 111 ml kg À1 . No data is available on the metabolism of exendin-(9-39), but it is expected that elimination of exendin-(9-39) would be similar to that of its parent peptide, exenatide, which is primarily eliminated through glomerular filtration followed by proteolytic degradation [19] . Furthermore, PK of exendin-(9-39) have not been previously studied and reported in children with HI.
In this study, PK data from three clinical studies of exendin-(9-39) in patients with HI were used to develop the first population pharmacokinetic (PopPK) model to (1) describe the distribution and elimination of exendin-(9-39), and (2) identify and quantify the effects of patient characteristics on the PK of exendin-(9-39). In addition, the final PopPK model was used with toxicological findings from preclinical studies to propose the optimal dosing regimen for future clinical trials in neonates with HI.
Methods

Preclinical studies
Juvenile toxicology studies were conducted in Sprague Dawley rats (7 ± 1 days of age) and beagle dogs (14 ± 2 days of age) in compliance with the US Food and Drug Administration Good Laboratory Practice Regulations. Exendin-(9-39) was administered via three times daily subcutaneous dosing. A total of 152 rats were assigned to receive 0, 20 . TK parameters evaluated for dose selection included maximum plasma concentrations (C max ) and area under the curve from zero to the last time point (AUC 0-last ). The human equivalent dose (HED) was then determined from the no observed adverse effect levels (NOAELs) identified in the rat and dog toxicology studies using the following equations [20] :
where k in Equation 1 is a conversion factor with standard values of 0.162 and 0.541 for rat and dog species, respectively. In Equation 2, the reference animal weights were 0.15 kg and 10 kg for rat and dog species, respectively; the mean body weight of neonates with HI (3.7 kg) was used as the human weight [21] . The maximum recommended starting dose (MRSD) for neonatal clinical studies was then derived by dividing the HED from the most sensitive species (i.e., the species from which the lowest HED was identified) by a safety factor of 10 [20] . This default safety factor was chosen because there are no additional safety concerns from animal studies (e.g., steep dose response curve, severe/nonmonitorable toxicities, nonlinear pharmacokinetics, etc.) that justify an increase in the safety factor [20] .
Clinical studies
Three open-label, two-period crossover pilot clinical studies were conducted with several exploratory doses of exendin-(9-39) in different populations of patients with HI at The Children's Hospital of Philadelphia. All three studies were approved by the human subjects committee of The Children's Hospital of Philadelphia and the U.S. Food and Drug Administration. Informed consent was obtained from all subjects or their legally authorized representatives. Assent was obtained from subjects under 18 when indicated. The three studies were registered on clinicaltrials.gov with the following identifying numbers: NCT00571324, NCT00897676, NCT00835328. The Effect of Exendin-(9-39) on Glycaemic Control in Subjects with Congenital Hyperinsulinism (later referred to as the Adult Study) was a completed clinical trial in older adolescents and adults with K ATP HI [16] . Subjects were excluded if they had acute diseases, a history of systemic chronic conditions, or were treated with medications that alter glucose metabolism (e.g., glucocorticoids, β-agonists, diazoxide and octreotide) [16] . The study was aimed at examining the effect of exendin-(9-39) on glucose metabolism. Fasted subjects received an IV infusion of exendin-(9-39) at 0.02, 0.06, 0.1 mg kg À1 h À1 for 2 h each or vehicle (0.9% NaCl) for 6 h in 2 consecutive days in random order. The primary outcomes were blood glucose and exendin-(9-39) levels. Secondary outcomes were insulin, GLP-1 and glucagon levels. Plasma samples for exendin-(9-39) concentration determination were obtained at 60 and 120 min after initiation of each dose and hourly for 3 h post infusion. The Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity (later referred to as the Children Study) was a clinical trial in children aged 6 months to 18 years with K ATP HI. The goal of the study was to examine the effect of exendin-(9-39) on phenotypic characteristics in HI, including fasting hypoglycaemia and protein-induced hypoglycaemia. For the investigation of the effect of exendin-(9-39) on fasting blood glucose levels, fasted subjects either received one of the two dosing regimens of exendin-(9-39) IV infusion (0.06, 0. The primary outcome was glucose infusion rate needed to maintain euglycaemia. Secondary outcomes were insulin, glucagon and exendin-(9-39) levels. Plasma samples for exendin-(9-39) concentration determination were obtained at half the infusion time, at the end of infusion, and hourly for 3 h post infusion.
Bioanalytical methods
The concentration of exendin-(9-39) in plasma samples collected from the clinical studies was quantified by liquid chromatography tandem mass spectrometry (LC-MS/MS) in the same laboratory. The LC-MS/MS method has been validated for quantification of exendin-(9-39) plasma concentrations as described previously [22] . Briefly, 95 μl of thawed plasma sample out of 1 ml in total that was withdrawn from the subjects was combined with 5 μl of 20-fold internal standard stock solution. Twenty-five μl of the resulting mixture was used for solid-phase extraction and the subsequent chromatographic analysis. Sample processing time was limited to 1 h to minimize degradation. Single reaction monitoring of m/z transitions 842.9 → 991.8 and 848.2 → 998.8 was used to quantify exendin-(9-39) in plasma samples and the added isotopically labelled internal standard, respectively. The calibration curve had a linear range of 10-1390 ng ml À1 , and the limit of detection was 1.3 ng ml À1 .
PopPK model development
The PopPK model was constructed using nonlinear mixedeffects modelling (NONMEM version 7.3, ICON Development Solutions, Hanover, Maryland) with first order conditional estimation (FOCE) with interaction method. Exendin-(9-39) concentration-time data from clinical studies were fitted to one-and two-compartmental linear PK models for the base model development. The interindividual variability was described using a log-normal distribution model. Residual error was initially modelled using a proportional, a combined additive and proportional error, or a Poisson error model. Following selection of the base model, the covariate models were built using a stepwise approach as previously described [23, 24] . First, the effects of weight (body size) on all PK parameters was investigated using an allometric model:
where TVP is the typical value of PK parameters in individuals with WT i ; θ TVP describes typical PK parameters for an individual with weight equal to the reference weight WT ref ; and θ a is an allometric power parameter. The standard adult weight of 70 kg was used as WT ref , and θ a was either estimated or fixed to 0.75 for clearance and 1 for volumes based on physiologic consideration of the impact of size on metabolic rate [25] .
After the effects of weight were accounted for in the model, a model for other biological covariates (i.e., age, creatinine clearance [CrCL], and gender) was built using a stepwise selection approach. CrCL in ml min (5) where Scr stands for serum creatinine in mg dl À1 . After the effects of biological covariates were incorporated in the model, the effects of patient groups (paediatric vs. adult) on PK parameters were tested to produce the final model. In addition, a sigmoidal maturation model was used to explore the effect of age on CrCL. For the patient groups covariate, the paediatric group included patients from the Children Study and the Neonate Study, and the adult group included patients from the Adult Study. Additionally, the patients were re-assigned to separate neonates (i.e., subjects from the Neonate Study) from the rest of the subjects to explore the effects of patient groups (neonates vs. others) on PK parameters. This sequential approach was used to distinguish changes in PK parameters related to weight and other biological covariates from those related to different patient groups. The serum drug concentrations below 10 ng ml À1 (the lower limit of quantification, LLOQ) were handled as fixedpoint censored observations, and the maximum likelihood estimation approach was used to fit the model to all including the censored observations based on the M3 approach proposed by Beal et al. [28] . The likelihoods for all data were maximized with respect to the model parameters, and the likelihood for a censored concentration was taken to be the likelihood that this observation was truly below the LLOQ. The likelihood ratio test and typical diagnostic plots were used to compare goodness-of-fit for the nested models and select statistically significant covariates [29] . A difference in objective function values between models greater than 6.64 was selected as the critical value, which corresponded to a significance level of 0.01 at one degree of freedom in the χ 2 distribution. A bootstrap resampling technique was used to estimate the confidence interval of parameters and assess the stability of the final model [23, 29] . Due to the presence of two distinct study populations in this analysis, a stratified sampling approach was used to obtain bootstrap samples in order to match the numbers of adult and paediatric subjects from the original data [23] . The results from 1000 successful runs were recorded; the mean and 95% confidence interval for population parameters were obtained and compared with the final model estimates from the original data. The posterior predictive model check was used to evaluate the ability of the final model to describe the observed exposure parameters [30] [31] [32] . The 10th, 50th (median) and 90th percentile of the C max and area under the curve from zero to infinity (AUC 0-inf ) of observed data were computed and selected as the test statistics for the posterior predictive model check. The posterior predictive distribution of test statistics from 1000 simulated data sets using the final PopPK model was computed and compared with observed test statistics, and the P-value (P PPC ) was estimated by calculating the proportion of cases in which test statistics from the simulated data sets were above or below realized values of observed test statistics using the following equation [31, 33] :
where I(.) is the indicator function which takes the value 1 when its argument is true and 0 when the argument is false. T(y, θ) is the realized value of observed test statistics, and T y rep i ; θ À Á is the test statistic from simulated data sets i (i ranging from 1 to 1000) [31, 33] . A P-value of <0.05 or >0.95 would indicate significant differences between observed test statistics and the posterior distribution of the test statistics in the simulated data sets, and that the model did not adequately describe the C max or AUC 0-inf of the observed data. In addition, prediction-corrected visual predictive check was used to evaluate the performance of the final model [34] . The final PopPK model was then used to estimate C max and AUC 0-inf following the administration of different exendin-(9-39) regimens in neonates with HI. The dosage regimens tested in the simulation were 0.02, 0.04, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8, 1, 2, 3, 5 and 6 mg kg À1 h À1 infused intravenously over 6 or 9 h. A total of 1000 simulated subjects with the reported mean body weight of 3.7 kg in neonates with HI were included in the analysis.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [35] , and are permanently archived in the Concise Guide to PHARMA-COLOGY 2017/18 [36] .
Results
Preclinical studies
In the rat study, the only statistically significant findings were decreased red cell mass values in female rats, increased serum glucose concentrations in female rats, and decreased serum triglyceride concentrations in male rats at the end of the recovery period on Day 43. In the dog study, there were sporadic occurrences of statistically significant changes in haematology, serum chemistry and coagulation parameters, but many of them were small in magnitude without the demonstration of dose dependency. These findings in rats and dogs were considered non-adverse with no or unclear association with exendin-(9-39) administration. Therefore, NOAELs in rats and dogs were the highest doses tested, i. NOAELs of rat and dog species, respectively. After the application of a safety factor of 10, the MRSD was calculated to be 21.9 mg kg À1 day À1 , which was higher than the result obtained by using standard conversion factors.
PopPK model
A total of 182 plasma levels of exendin-(9-39) from 26 subjects were included in the development of the PopPK model, of which 16 observations below the LLOQ were included in the analysis. Demographic data of the paediatric and adult groups are summarized in Table 1 , and the concomitant medications of all subjects are described in Table S1 . In the paediatric group including ten children and seven neonates, the median age was 3 years (range: 0.06-15). In the adult group including nine older adolescents and adults, the median age was 19 years (range: 15-47). Based on the difference in objective function values (P < 0.01), PK of exendin-(9-39) were best described by a two-compartmental linear PK model using the NONMEM subroutine ADVAN3 TRANS4. Four PK parameters were described in the subroutine, including clearance [3] , central volume (V1), intercompartmental clearance [25] , and peripheral volume (V2). Including interindividual variability terms for V1, Q and V2 failed to achieve model convergence and/or generated poorly parameter estimates, with percent coefficient of variation (%CV) over 50%. Therefore, only the interindividual term of CL was retained in the model. Among the different residual error models tested, the Poisson error model was the most stable with lower objective function value, and Table 1 Demographic data of the paediatric and adult groups for population pharmacokinetic model development. The paediatric group is further divided into neonates and children with subjects in the Neonate Study and the Children Study, respectively. Data are presented as median (range)
Paediatric group (n = 17)
Adult group (n = 9) Neonates (n = 7)
Children (n = 10) Others 1 (unknown) 1 (unknown) 0
Number of exendin-(9-39) plasma levels 34 67 81
therefore it was used to describe the residual variability in the analysis. After the effects of weight on PK parameters (CL, V1, Q, V2) were accounted for using allometric scaling, none of the other covariates tested (age, CrCL, gender and patient groups) had significant effects on CL (P > 0.01). The final PopPK model was described as following:
where PK parameters with the 'TV' subscript represent typical population values in reference adult subjects with body weight of 70 kg; WT represents body weight in kilograms. The final PopPK model parameter estimates are presented in Table 2 . All parameters were estimated with good precision (%CV < 50%). CL TV , V1 TV , Q TV , and V2 TV were 11.6 l h À1 , 9.59 l, 2.20 l h À1 and 8.89 l, respectively. Based on these parameter estimates, the calculated CL and elimination half-life for the paediatric group with median weight of 15 kg were 3.65 l h À1 and 2.34 h, respectively; the calculated CL and elimination half-life for the adult group with median weight of 69 kg were 11.5 l h À1 and 3.42 h, respectively.
For the final model with covariates, the standard model diagnostic plots are shown in Figure 1 . The observed concentrations were generally in accordance with the predicted concentrations with the exception of the concentration range below 20 ng ml À1 , in which the model underestimated the observed concentrations possibly due to biases introduced by the M3 method in handling the PK observation below the LLOQ. From the original data set, 1500 replicate data sets were generated and used to evaluate the stability of the final model. NONMEM achieved successful minimization steps for 1261 out of 1500 (84.1%) replicate data sets, suggesting that the final PopPK developed in this study was relatively stable. The results from the first 1000 runs are shown in Table 2 . The mean population parameters obtained from the bootstrap procedure were similar to the parameter estimates of the original data set, again indicating the stability of the final PopPK model [23] . However, there were relatively large 95% confidence intervals for Q and V2, and the interindividual variance of CL, η CL , from the bootstrap procedure, which could be due to the limited number of subjects included in this analysis and/or the presence of influencing subjects with PK parameters and observations that significantly deviated from population reference values. A posterior predictive model check was used to evaluate the ability of the final PopPK model to describe exposure parameters of observed data for dose selection in future clinical studies. Test statistics were computed for each of the 1000 simulated data sets from the final PopPK model. As shown in Figure 2 , the observed values were within posterior predictive distributions with estimated P-values between 0.05 and 0.95 for each test statistic, suggesting that the model was able to describe and predict the C max and AUC 0-inf of observed data reasonably well. Posterior Table 2 Parameter estimates of the final population pharmacokinetic model and the model stability using bootstrap resampling approach predictive check for adult subjects and paediatric subjects separately is presented in Figure S1 , and again all P PPC values were between 0.05 and 0.95. The result from predictioncorrected visual predictive check is presented in Figure S2 , which indicates the lack of random effects misspecification, as there is no apparent discrepancy between observations and model predictions. , respectively. The C max values following 6 and 9 h IV infusion with the same infusion rate were very similar, probably due to the relatively short half-life of the exendin-(9-39) and the achievement of steadystate condition at 6 h. Using a factor of 10 as the safety margin based on the AUC 0-last value at steady-state in rats at the NOAEL, the AUC 0-inf for the MRSD was calculated to be (757 500 ng h À1 ml
À1
)/10 = 75 750 ng h À1 ml
, which approximated the AUC 0-inf produced by 3 mg kg À1 h À1 infused over 9 h or 27 mg kg À1 day À1 (7.72 × 10 4 ng h À1 ml
). With this dosage regimen, the simulated C max value was 2.31 × 10 3 ng ml
, and the safety margin based on the C max value in male rats at the ) ≈ 27. In comparison, the MRSD obtained from the HED conversion was 10 mg kg À1 day À1 and 21.9 mg kg À1 day À1 using (Equations 1 and 2), respectively, and both values were more conservative compared to that obtained using the AUC 0-last at the NOAEL and PopPK model predictions (27 mg kg À1 day À1 ) ( Table 3 ).
Figure 2
Model evaluation of exendin-(9-39) population pharmacokinetic model using the posterior predictive check for all subjects. Posterior predictive distributions of test statistics from 1000 simulated data sets are presented. The vertical line on each histogram represents the observed value of the test statistic. C max _10, C max _50, and C max _90 represent C max values at 10th, 50th (median), and 90th percentile, respectively. AUC 0-inf _10, AUC 0-inf _50, and AUC 0-inf _90 represent AUC 0-inf values at 10th, 50th (median), and 90th percentile, respectively
Discussion
Poorly treated HI could result in delays in development and permanent neurological impairment in infants and children. Diazoxide is the preferred medical treatment in HI, but it is often ineffective for patients with K ATP HI. Patients with diffuse HI who are refractory to first-and second-line pharmacotherapy may need a near-total pancreatectomy, which could produce serious long-term complications [3] . Given that HI is such a complicated disease that is challenging to manage, several novel treatments are being developed in order to improve therapeutic outcomes for these patients. Among the investigational agents, exendin-(9-39), an inverse GLP-1 receptor agonist, has been shown to decrease insulin secretion and increase blood glucose levels in preclinical and human studies [15] [16] [17] [18] 37] . The first objective of this study was to construct a PopPK model using PK observations from three clinical studies. PopPK analysis with NONMEM showed that exendin-(9-39) concentration-time profiles were well characterized by a two-compartmental linear PK model. The model estimates of CL, V1, Q and V2 for a typical 70-kg adult were 11.6 l h À1 , 9.59 l, 2.20 l h À1 and 8.89 l, respectively. The PK characteristics of exendin-(9-39) reported in this study were similar to those typically observed with therapeutic peptides. Many peptides are rapidly cleared from systemic circulation primarily due to enzymatic proteolysis and/or renal elimination [38] . Hydrophilic peptides with molecular weight < 2-25 kDa are likely to undergo rapid filtration through renal glomeruli and have high renal clearance due to limited reabsorption through the renal tubule [38] . However, no data on renal elimination and metabolism of exendin-(9-39) is available. The parent peptide of exendin-(9-39), exenatide, is resistant to rapid proteolytic cleavage by peptidases and is predominately eliminated by glomerular filtration and proteolytic degradation in the renal tubule [39] . The elimination half-life of exendin-(9-39) was relatively shorter compared to that of exenatide (~2.5 h) [40] , and the CL of exendin-(9-39) is relatively higher than the normal glomerular filtration rate in humans. These observations indicated the presence of low proteolytic activity in other tissues in addition to renal elimination (i.e., glomerular filtration and the subsequent intraluminal metabolism) [41] . In the final PopPK model, following the allometric scaling of PK parameters, CrCL was not shown to significantly affect the CL of exendin- . This lack of effect may seem unexpected, but it could be explained by relatively narrow ranges of CrCL in the original data set due to lack of subjects with moderate to severe renal impairment. In addition, a PK study on therapeutic doses of exenatide found that mild renal impairment did not produce significant reduction in CL, while moderate renal impairment and end-stage renal disease significantly decreased CL of exenatide [40] . As exenatide and exendin-(9-39) share similar PK characteristics, it is reasonable to infer that the effects of renal impairment on the PK of the two therapeutic agents are likely to be similar. Nevertheless, more studies are needed in order to determine the PK of exendin-(9-39) in patients with moderate to severe renal impairment. As the size of peptides is between that of small molecule drugs and large proteins, the volume of distribution of peptides is relatively small, with typical V1 values of~3-8 l that slightly exceed the plasma volume, and typical steady-state volume of distribution (V ss ) in the range of extracellular fluid volume (~15 l in 70-kg adults) [39] . In 70-kg adults, V1 and V ss of exendin-(9-39) were estimated to be 8.57 l and 15.6 l, respectively; both values were consistent with reported values of peptides. Sixteen out of the 182 PK samples included in the final analysis were below the LLOQ. It is well known that omission of the PK samples below LLOQ causes substantial bias to parameter estimates in the population PK analysis [42] , and in this study excluding these observations from the analysis produced poorly estimated parameter estimates for V2 with CV% ≈ 61%. As it was very difficult to obtain sufficient PK samples in paediatric subjects with HI, a rare orphan disease, it would be very useful to include the PK samples with values below the LLOQ in the analysis to create a population PK model that can best describe the disposition of exendin-(9-39) in these patients. Among the modelling methods that handle PK observations below LLOQ in PopPK analysis, a likelihood-based approach or the M3 method proposed by Beal et al. had been shown to produce consistent model parameter estimates [28, 42, 43] , and this method has been successfully used to develop PopPK models using PK data with many observations below LLOQ to generate reliable model parameter estimates by fitting the developed models to the complete data sets [44, 45] .
The secondary objective of this study was to select a safe and potentially more effective dosing regimen of exendin-(9-39) in future clinical studies involving neonates with HI based on the final PopPK model and preclinical toxicity data. According to the published results of the Adult Study, the exendin-(9-39) dose studied (0.02, 0.06 and 0.1 mg kg À1 h À1 for 2 h each) significantly increased fasting glucose levels compared to vehicle [16] . Because neonates have a more severe phenotype of HI compared to adolescents and adults [9] , they are likely to require higher exendin-(9-39) doses due to potentially different exposure-response relationships. Thus, a PK and efficacy approach with no extrapolation from adult efficacy data would be required for the development of exendin-(9-39) in neonates [46, 47] . It is therefore, reasonable to include doses that produce higher exposure than that associated with the studied adult dose in future neonate studies [47] . To determine a dosage regimen in neonates that could achieve adequate exposure for the evaluation of efficacy while maintaining acceptable safety margins, this study used a comparative approach to select the MRSD based on the traditional HED conversion method and the pharmacokinetically guided method. The study analysis showed that the MRSD determined from modelling and simulation based on the AUC 0-last at the NOAEL and predicted AUC 0-inf using the developed PopPK model was higher than that derived from the HED using standard conversion factors, allowing higher doses to be considered, as the pharmacokinetically guided method appeared to be a more rational approach in the presence of adequate preclinical toxicology data and clinical PK data. Nevertheless, this assumption would still need to be validated in future clinical trials in neonates, and the MRSDs determined by all approaches will be incorporated into the dose escalation scheme for future clinical studies in neonates with HI. The efficacy of the new dosing scheme determined from this study would be evaluated by the glycaemic response it produces in neonates (i.e., its ability to maintain euglycaemia without supraphysiological supplementation of glucose) in future safety/efficacy trials. In summary, this was the first study to examine the population pharmacokinetics of exendin-(9-39) in HI patients of various age groups. This study showed that the final PopPK model could reasonably describe the observed plasma concentrationtime profiles of exendin- . One limitation of the study was the small sample size, which restricted the ability of the model to estimate interindividual variability of PK parameters other than CL with good precision. Further studies are needed to improve the current PopPK model with more PK observations. Nevertheless, this study should serve as an important starting point to enable a more targeted dosing approach to link dose exposure to desired glycaemic response to exendin-(9-39).
a total of 1000 simulated data sets are presented. The vertical line on each histogram represents the observed value of the test statistic. C max _10, C max _50, and C max _90 represent C max values at 10th, 50th (median), and 90th percentile, respectively. AUC 0-inf _10, AUC 0-inf _50, and AUC 0-inf _90 represent AUC 0-inf values at 10th, 50th (median), and 90th percentile, respectively Figure S2 Model evaluation of exendin-(9-39) population pharmacokinetic model using prediction-corrected visual predictive check. The solid red line represents the median prediction-corrected observed plasma concentration in ng ml À1 , and the simulation-based 95% confidence interval for the median is represented by the semitransparent red area. The dashed red lines represent the observed 5% and 95% percentiles, and the semitransparent blue fields show the 95% confidence intervals for the model predicted percentiles. Prediction-corrected observed plasma concentrations are shown in blue circles
